Cantargia: Inclusion of AML & MDS - Redeye

We have now included acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS) in our sum-of-the-parts valuation. As mentioned before, this has a minor impact on our base case, but it demonstrates the potentially broad application of anti-IL1RAP therapy, including in haematological cancers.

Länk till analysen i sin helhet: https://www.redeye.se/research/943276/cantargia-inclusion-of-aml-mds?utm_source=finwire&utm_medium=RSS